Janssen Presents Updated Data on First-in-Class Talquetamab at ASCO Suggesting Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
I-Mab
I-Mab is a clinical-stage biopharmaceutical company that commits to the discovery, development, and commercialization of novel or highly differentiated biologics. The company aims to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. As a company not involved in COVID-19 vaccines, the health care company stock has been performing extremely well. Impressively, it has risen by more than 220% over the past year with its bullish trend still intact.
Investors have been keeping their eyes on IMAB stock in response to the company’s early data on Uliledlimab/Atezolizumab combo in advanced cancer settings. More detailed data of the trial will be unveiled at the 2021 American Society of Clinical Oncology Annual Meeting which will be taking place next month.
(FMTX) - Forma Therapeutics Olutasidenib Achieves 33% Remission Rate In Acute Myeloid Leukemia Patients benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Patients treated with Opdivo plus Yervoy with two cycles of chemotherapy showed sustained improvements in overall survival and progression-free survival and increased duration of response vs. chemotherapy at two years Dual immunotherapy-based combination demonstrated clinical benefit across key subgroups of patients, regardless of PD-L1 expression level or histology Data to be featured in an oral presentation during … Patients treated with Opdivo plus Yervoy with two cycles of chemotherapy showed sustained improvements in overall survival and progression-free survival and increased duration of response vs. chemotherapy at two years Dual immunotherapy-based combination demonstrated clinical benefit across key subgroups of patients, regardless of PD-L1 expression level or histology
Gilead-Kite Oncology to Present Transformative Science From Growing Portfolio at ASCO 2021
Gilead Sciences, Inc. and Kite, a Gilead Company, today announced that 16 abstracts representing the breadth of the Gilead-Kite Oncology portfolio will be presented at the American Society of Clinical Oncology Annual Meeting from June 4-8, 2021. The abstracts, including two oral presentations, expand on the clinical profiles of Gilead’s antibody-drug conjugate as well as Kite’s chimeric antigen receptor T-cell … Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced that 16 abstracts representing the breadth of the Gilead-Kite Oncology portfolio will be presented at the American Society of Clinical Oncology Annual Meeting from June 4-8, 2021. The abstracts, including two oral presentations, expand on the clinical profiles of Gilead’s antibody-drug conjugate (ADC), as well as Kite’s chimeric antigen receptor (CAR) T-cell therapies across a range of cance